OLMUTINIB is also an EGFR inhibitor (Roskoski, 2019), and given the biological functions associated with LAMA2, it suggests that targeting LAMA2 and EGFR may hold therapeutic value for RA. Here, EGFR is linked to rheumatoid arthritis.